Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual disease

BACKGROUND: About half of AML patients achieving complete remission (CR) display measurable residual disease (MRD) and eventually relapse. FLYSYN is an Fc-optimized antibody for eradication of MRD directed to FLT3/CD135, which is abundantly expressed on AML cells. METHODS: This first-in-human, open-...

Descripción completa

Detalles Bibliográficos
Autores principales: Heitmann, Jonas S., Schlenk, Richard F., Dörfel, Daniela, Kayser, Sabine, Döhner, Konstanze, Heuser, Michael, Thol, Felicitas, Kapp-Schwoerer, Silke, Labrenz, Jannik, Edelmann, Dominic, Märklin, Melanie, Vogel, Wichard, Bethge, Wolfgang, Walz, Juliane S., Große-Hovest, Ludger, Steiner, Martin, Jung, Gundram, Salih, Helmut R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10433561/
https://www.ncbi.nlm.nih.gov/pubmed/37587502
http://dx.doi.org/10.1186/s13045-023-01490-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10433561/
https://www.ncbi.nlm.nih.gov/pubmed/37587502
http://dx.doi.org/10.1186/s13045-023-01490-w

Ejemplares similares